Authors
Latest:
HIV CRISPR Therapy Fast-Tracked by the FDAThe phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.
Latest:
The US Will Transition to Trivalent Vaccines for Next Year's Influenza SeasonSince changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.
Latest:
Expanded Treatment Options for Multi-Drug Resistant Infections in ChildrenIn the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.
Latest:
UTIs: Why Did You Have to Go and Make Things so Complicated?Although hospitalizations due to urinary tract infections have increased, there are some investigational antibiotics in clinical trials. Here is a review of some of these therapies in the pipeline.
Latest:
From Pandemic to EndemicA research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.
Latest:
FDA Approves Combination Antibiotic for Treatment of Complicated Urinary Tract InfectionsCefepime-enmetazobactam (Exblifep, Orchid Pharma) was given the federal nod for the indication of treating complicated urinary tract infections (cUTI) in adults.
Latest:
Community-Acquired Candida Glabrata Empyema: An Atypical Diagnosis Not to MissAlthough this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
Latest:
IV Push Administration for Outpatient Parenteral Antimicrobial TherapyInvestigators designed a quasi-experimental pre- and post-intervention analysis comparing a pre-intervention cohort receiving IV drip antibiotic infusion with a post-intervention cohort receiving IVP administration.
Latest:
Barriers to Health Care Transition in Adolescents and Young Adults With Early Acquired HIV InfectionUnique challenges can affect the success of the shift from pediatric to adult care settings.
Latest:
Multidisciplinary Perspectives on HIV TreatmentA multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Latest:
Top 5 Tips for Teaching ID LearnersThe latest article from SIDP offers a Top 5 list of how to precept a learner on an infectious disease rotation.
Latest:
Combination Antifungal for Invasive Mucormycosis: Yay or Nay?There is limited and conflicting data regarding the role of combination antifungal therapy for treatment of invasive mucormycosis.
Latest:
Maternal COVID-19 Vaccination, Infection Boosts Infant Antibody ResponseNatural infection plus COVID-19 vaccination in pregnant mothers conferred more durable antibody responses in infants than natural infection alone.
Latest:
What to Expect With Influenza in the Era of COVID-19Here are some insights into this upcoming 2021-2022 influenza season as well as concerns of the twindemic and addressing both the seasonal and pandemic viruses simultaneously.
Latest:
HIV and Aging in the Era of Antiretroviral Therapy: Considerations in Clinical CareWith the population of adults with HIV growing older, incorporating age-based screenings, comprehensive assessments, and morbidity management into routine HIV care is essential in improving health outcomes and quality of life.
Latest:
Nonventilator Hospital-Acquired Pneumonia: Epidemiology, Prevention, and Where It Is NowThe management of hospital-acquired pneumonia requires use of preventive bundles, mitigative of risk factors, and prompt diagnosis with initiation of treatment when highly suspected.
Latest:
Clinical Considerations in Conducting Antifungal Susceptibility TestingAccess to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.
Latest:
A Case of Mycobacterium Chimaera Infective EndocarditisNonspecific, nondolent symptoms make this disease difficult to diagnose.
Latest:
A Review of the Currently Available Monoclonal Antibodies for COVID-19Outside of vaccines, these underutilized therapies are the best defense against severe disease.
Latest:
Celebrating 30 Years: The Past, Present, and Future of the Society of Infectious Diseases Pharmacists (SIDP)Introducing “Bench to Bedside With SIDP,” a new column covering everything from antimicrobial stewardship and pharmacokinetics/pharmacodynamics to mentorship, preceptorship, and more.
Latest:
A Viral Colonial Legacy: HIV, Monkeypox Emerged Due to Ongoing Colonial Viral NeglectSimilar to HIV, the colonial and postcolonial history is fundamental to the biology of this monkeypox outbreak.
Latest:
SPREADing the Love: The Importance of Mentorship in PharmacyIn the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.
Latest:
Restarting Therapy in Patients with HIVAddressing patients with HIV who have fallen out of care, Shauna Applin, ARNP, provides clinical insights on treatment options and best practices for restarting therapy.
Latest:
A Case of Varicella-Zoster Meningitis Causing Postoperative Fevers After Umbilical Hernia RepairDue to worsening headaches and unrevealing cross-sectional imaging and ascites fluid analyses, this patient's differential evolved toward a central nervous system source.
Latest:
Are We at a Breaking Point for Adoption of Updated Susceptibility Interpretive Criteria?The implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.
Latest:
Antibiotic Options for MRSA Bacteremia: Are We Still Stuck in “Mississippi Mud?”Here is a review of therapies for treating this bacterium.
Latest:
Ceftriaxone Dosing: Once or Twice Daily?In the latest column from SIDP, clinicians discuss that along with the once-daily dosing for many indications, there are also compelling indications for twice-daily dosing.
Latest:
Early Experience With the BioFire Pneumonia PanelA balance between antimicrobial stewardship and the search for multidrug-resistant organisms.
